Status:
COMPLETED
Invasive Left Heart Catheterization Registry
Lead Sponsor:
Samsung Medical Center
Conditions:
Heart Failure With Preserved Ejection Fraction
Left Ventricular Diastolic Dysfunction
Eligibility:
All Genders
19+ years
Brief Summary
Retrospectively enrolled suspicious of heart failure with preserved ejection fraction (HFpEF) patients who underwent left heart catheterization with the measurement of left ventricular end-diastolic p...
Detailed Description
Heart failure (HF) with preserved ejection fraction (HFpEF) remains a poorly understood clinical syndrome without effective targeted therapies. The clinical syndrome of HFpEF develops from a complex i...
Eligibility Criteria
Inclusion
- Left ventricular ejection fraction \> 50%
- Patients who had a symptom and/or signs of heart failure (dyspnea on exertion, chest discomfort, fatigue, dizziness, or ankle edema)
- Patients who underwent left heart catheterization with the measurement of left ventricular end-diastolic pressure
Exclusion
- Left ventricular ejection fraction \<50%
- Acute coronary syndrome
- More than moderate valvular heart disease
- Primary cardiomyopathies such as dilated cardiomyopathy and hypertrophic cardiomyopathy, amyloidosis
- Pulmonary arterial hypertension
- Heart transplantation
- Constrictive pericarditis
- Stress-induced cardiomyopathy
Key Trial Info
Start Date :
December 13 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2021
Estimated Enrollment :
404 Patients enrolled
Trial Details
Trial ID
NCT04505449
Start Date
December 13 2019
End Date
March 31 2021
Last Update
October 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea, 06351